Oppenheimer Asset Management Inc. Lowers Stake in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Oppenheimer Asset Management Inc. cut its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTHGet Rating) by 12.4% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 5,409 shares of the medical equipment provider’s stock after selling 767 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in Lantheus were worth $357,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Vanguard Group Inc. boosted its position in shares of Lantheus by 32.9% in the first quarter. Vanguard Group Inc. now owns 5,742,083 shares of the medical equipment provider’s stock worth $317,595,000 after acquiring an additional 1,422,269 shares during the last quarter. Lord Abbett & CO. LLC acquired a new stake in shares of Lantheus in the first quarter worth approximately $71,663,000. Hood River Capital Management LLC boosted its position in shares of Lantheus by 29.8% in the first quarter. Hood River Capital Management LLC now owns 1,079,197 shares of the medical equipment provider’s stock worth $59,690,000 after acquiring an additional 247,868 shares during the last quarter. Bank of New York Mellon Corp boosted its position in shares of Lantheus by 2.7% in the first quarter. Bank of New York Mellon Corp now owns 629,033 shares of the medical equipment provider’s stock worth $34,791,000 after acquiring an additional 16,422 shares during the last quarter. Finally, Assenagon Asset Management S.A. boosted its position in shares of Lantheus by 127.4% in the second quarter. Assenagon Asset Management S.A. now owns 572,691 shares of the medical equipment provider’s stock worth $37,815,000 after acquiring an additional 320,846 shares during the last quarter. 98.14% of the stock is currently owned by hedge funds and other institutional investors.

Lantheus Trading Down 5.5 %

LNTH opened at $55.82 on Thursday. The firm has a market capitalization of $3.84 billion, a P/E ratio of 37.46 and a beta of 0.79. The firm’s 50 day moving average is $70.64 and its 200-day moving average is $70.43. Lantheus Holdings, Inc. has a 52-week low of $23.51 and a 52-week high of $87.47. The company has a quick ratio of 1.98, a current ratio of 2.13 and a debt-to-equity ratio of 0.24.

Lantheus (NASDAQ:LNTHGet Rating) last posted its quarterly earnings data on Thursday, November 3rd. The medical equipment provider reported $0.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.75 by $0.15. The company had revenue of $239.29 million for the quarter, compared to analyst estimates of $228.52 million. Lantheus had a net margin of 13.35% and a return on equity of 37.77%. Analysts expect that Lantheus Holdings, Inc. will post 3.51 EPS for the current fiscal year.

Insider Activity

In related news, Director Brian A. Markison sold 41,812 shares of the company’s stock in a transaction on Thursday, September 8th. The shares were sold at an average price of $84.24, for a total value of $3,522,242.88. Following the sale, the director now directly owns 32,608 shares of the company’s stock, valued at $2,746,897.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, CFO Robert J. Jr. Marshall sold 4,828 shares of the stock in a transaction dated Tuesday, October 18th. The shares were sold at an average price of $73.41, for a total transaction of $354,423.48. Following the transaction, the chief financial officer now owns 126,065 shares of the company’s stock, valued at $9,254,431.65. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Brian A. Markison sold 41,812 shares of the stock in a transaction dated Thursday, September 8th. The stock was sold at an average price of $84.24, for a total transaction of $3,522,242.88. Following the transaction, the director now directly owns 32,608 shares in the company, valued at approximately $2,746,897.92. The disclosure for this sale can be found here. Insiders have sold 66,098 shares of company stock worth $5,054,679 over the last 90 days. Company insiders own 1.60% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have weighed in on LNTH. Mizuho began coverage on shares of Lantheus in a research report on Wednesday, October 12th. They set a “buy” rating and a $105.00 price target on the stock. B. Riley reaffirmed a “buy” rating on shares of Lantheus in a research report on Thursday, August 25th. StockNews.com raised shares of Lantheus from a “hold” rating to a “buy” rating in a research report on Friday, November 4th. Jonestrading began coverage on shares of Lantheus in a research report on Thursday, October 6th. They set a “buy” rating and a $104.00 price target on the stock. Finally, SVB Leerink lifted their price target on shares of Lantheus from $110.00 to $120.00 and gave the company an “outperform” rating in a research report on Tuesday. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $102.80.

About Lantheus

(Get Rating)

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors.

Read More

Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings, Inc. (NASDAQ:LNTHGet Rating).

Institutional Ownership by Quarter for Lantheus (NASDAQ:LNTH)

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.